In addition, the BRIGHT study, which compared two second-generation BIs (Gla-300 vs. IDeg-100) head-to-head, has provided important information about the effectiveness and safety of Gla-300 in insulin-naïve individuals with T2DM and renal impairment. The gene discussed is INS; the disease is type 2 diabetes mellitus.